Huadong Medicine Co., Ltd
000963
Rangering i aksjer
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
Aksjekurs
$3.89
Markedsverdi
$6.83B
Endring (1 dag)
-2.22%
Endring (1 år)
-30.58%
Land
CN
Handel Huadong Medicine Co., Ltd (000963)
Kategori
Healthcare
Inntekter for Huadong Medicine Co., Ltd (000963)
Inntekter i Jun 2026 TTM: $604.11M
Ifølge Huadong Medicine Co., Ltd sine nyeste økonomiske rapporter er selskapets nåværende resultat $604.11M. I 2024 hadde selskapet et resultat på $589.32M, en økning sammenlignet med resultatet i 2023, som var $489.64M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Huadong Medicine Co., Ltd fra 2001 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $604.11M | 5.23% |
| 2025 | $574.08M | -2.59% |
| 2024 | $589.32M | 20.36% |
| 2023 | $489.64M | 11.43% |
| 2022 | $439.43M | -1.22% |
| 2021 | $444.87M | -15.85% |
| 2020 | $528.63M | 6.07% |
| 2019 | $498.37M | 19.34% |
| 2018 | $417.61M | 16.89% |
| 2017 | $357.26M | 31.78% |
| 2016 | $271.11M | 23.98% |
| 2015 | $218.66M | 15.48% |
| 2014 | $189.36M | 21.89% |
| 2013 | $155.35M | 23.01% |
| 2012 | $126.29M | 29.91% |
| 2011 | $97.22M | 29.50% |
| 2010 | $75.07M | -9.32% |
| 2009 | $82.78M | 100.08% |
| 2008 | $41.37M | -0.62% |
| 2007 | $41.63M | 84.19% |
| 2006 | $22.60M | 31.03% |
| 2005 | $17.25M | 50.58% |
| 2004 | $11.46M | 28.58% |
| 2003 | $8.91M | -7.36% |
| 2002 | $9.62M | -15.85% |
| 2001 | $11.43M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| $1.72B | 185.31% |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 192.09% |
IN
|
